Our Global Capital Confidence Barometer shows life sciences expectations continue to be positive, with 50% of executives planning to pursue M&A in the next year.
Life sciences M&A optimism resulted in record deal announcements first quarter
The implications of US tax reform for Ireland’s life sciences
Helping Ireland's life sciences achieve more on the global stage
Choose your deal strategy wisely
Life sciences deal intentions remain above trend
Medtech innovation for the aging world
The operating room of the future
Building value through creative deal structures
Investing in China for the long term
The need for alignment to achieve health outcomes for all
As populations age and chronic diseases become commonplace, health care will take an ever larger share of GDP. Scientific progress, augmented intelligence and a more empowered patient are driving changes in the delivery of health care to a personalized experience that demands health outcomes as the core metric. This is causing a power shift among traditional stakeholder groups, with new entrants (often not driven by profit) disrupting incumbents.
Innovation, productivity and access to patients remain the industry’s biggest challenges. These trends challenge the capital strategy of every link in the life sciences value chain, from R&D and product supply to product launch and patient-centric operating models.
Our Global Life Sciences Sector brings together a worldwide network of 11,000 sector-focused professionals to anticipate trends, identify their implications and help our clients create competitive advantage. We can help you navigate your way forward and achieve sustainable success in the new health-outcomes-driven ecosystem.
- It’s time for biopharma to embrace risk sharing
- Beyond Borders 2016: Biotech financial performance
- Beyond borders: returning to Earth
- Beyond Borders 2016: Biotech deals
- Beyond Borders 2016: Biotech financing
- Beyond borders: Reaching new heights – Biotechnology Industry Report 2015
- Megatrends – Health reimagined
- EY M&A Outlook and Firepower Report 2017
- The Firepower Index and Growth Gap Report 2016
- Firepower Index and Growth Gap Report 2015: Focus, scale and growth drive explosive M&A
- Life Sciences: Global Corporate Divestment Study 2015
- Cash on prescription: Pharmaceutical companies and working capital management 2015
- Megatrends – Health reimagined
- Medical technology
The KDB is aimed at incentivising innovative R&D activities by taxing qualifying profits from patented inventions and copyrighted software at 6.25%. This following infographic showcases the 5 key areas Life Sciences companies should consider in accessing the benefits of KDB.
For more details, read EY’s KDB for Life Sciences report.
Connect with us
Stay connected with us through social media, email alerts or webcasts. Or download our EY Insights app for mobile devices.
Jillian Symes, EMEIA US Tax Desk Director, EY London, and Aidan Meagher, Irish Life Sciences Lead, look at how the significant new US Tax Cuts and Jobs Act will impact Irish life sciences companies.
Ian Collins, Partner and Head of R&D Tax Services, reflects on the key strengths of Ireland’s Life Sciences sector, the supports available and the innovations changing the way we do business.
Whether you’re transforming your business today, or transform the sector tomorrow. EY can help you do both better. Download our brochure.
EY discusses the Life Sciences sector
EY's Leanne Storan discusses the KDB and the benefits for Life Sciences companies in Ireland